secwatch.observer — SEC 8-K summary
======================================

Issuer:     Definium Therapeutics, Inc. (DFTX)
CIK:        0001813814
Form:       8-K
Filed at:   2025-04-21T23:59:59+00:00
Accession:  0001104659-25-036841
Event type: debt
Sentiment:  positive
Materiality: 0.65
Item codes: 1.01, 2.03, 3.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

MindMed amends credit facility, gets $42M new term loan; total capacity up to $120M
--------------------------------------------------------------------------------

- Restated credit facility provides up to $120M in term loans; $42M funded immediately to refinance existing debt.
- Interest rate lowered to greater of 10.25% or Prime+2.75%; maturity extended to April 1, 2029.
- Lenders may convert up to $7M of debt into common shares at $4.01-$9.00 per share.
- Additional $28M tranche available upon clinical/regulatory milestones; $50M discretionary tranche.
- Minimum liquidity covenant effective July 1, 2026 if milestones missed; waived if market cap >$500M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1813814/000110465925036841/0001104659-25-036841-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1813814/000110465925036841/tm2512703d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-036841

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer